BioNTech (BNTX) Downgraded by Zacks Investment Research to Hold

BioNTech stock has undergone multiple analysts rating changes in the recent past.  BioNTech Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of BioNTech traded up $5.63 on Wednesday, reaching $249.40. 1440038 shares of the stock traded hands, compared to its average volume of 3105790. Shares of BioNTech were trading at $249.40 on Wednesday. The firm’s 50 day moving average is $333.04 and its 200 day moving average is $205.86.BioNTech has a 12 month low of $244.50 and a 12 month high of $464.00. While on yearly highs and lows, BioNTech’s today has traded high as $250.98 and has touched $244.50 on the downward trend. See More Analyst Rating at: RATING

BioNTech Earnings and What to expect: 

BioNTech last released its quarterly earnings results on August 8th, 2021. The reported $10.77 earnings per share for the quarter, topping the consensus estimate of $8.35 by $2.42. The business had revenue of $5.31 billion for the quarter, compared to the consensus estimate of $3.27 billion. Its revenue was up 12599.8% compared to the same quarter last year. BioNTech has generated $0.07 earnings per share over the last year ($19.11 diluted earnings per share) and currently has a price-to-earnings ratio of 13.1. Earnings for BioNTech are expected to decrease by -10.29% in the coming year, from $37.71 to $33.83 per share. BioNTech has confirmed that its next quarterly earnings report will be published on Tuesday, November 9th, 2021. BioNTech will be holding an earnings conference call on Tuesday, November 9th at 8:00 AM Eastern. Interested parties can .

Earnings for BioNTech are expected to decrease by -10.29% in the coming year, from $37.71 to $33.83 per share. The P/E ratio of BioNTech is 13.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 14.74. The P/E ratio of BioNTech is 13.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 32.22. BioNTech has a P/B Ratio of 35.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

BioNTech (BNTX) Moving Average Technical Analysis

5 day Moving Average is $245.74 And 5 day price change is $13.26 (5.62%)  with average volume for 5 day average is 1,695,560. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $289.53 and 20 day price change is -$105.85 (-29.80%) and average 20 day moving volume is 3,092,565. 50 day moving average is $333.04  and 50 day price change is -$102.41 ( -29.11%)  and with average volume for 50 days is : 4,372,492. 200 day moving average is $205.86  and 200 day price change is $161.29 (183.06%)  and with average volume for 200 days is : 3,089,700.

Other owners latest trading in BioNTech :

  • On 10/13/2021 shares held by Hollencrest Capital Management were 907 which equates to market value of $0.25M and appx 0.00% owners of BioNTech
  • On 10/13/2021 shares held by Harbour Capital Advisors LLC were 6,330 which equates to market value of $1.73M and appx 0.50% owners of BioNTech
  • On 10/13/2021 shares held by Capital CS Group LLC were 1,400 which equates to market value of $0.36M and appx 0.30% owners of BioNTech
  • In total Institutional ownership equates to Institutional Ownership Percentage: 14.49% for BioNTech

See More Analyst Rating at: RATING